Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

The replication-competent HIV-1 latent reservoir is primarily established near the time of therapy initiation.

Abrahams MR, Joseph SB, Garrett N, Tyers L, Moeser M, Archin N, Council OD, Matten D, Zhou S, Doolabh D, Anthony C, Goonetilleke N, Karim SA, Margolis DM, Pond SK, Williamson C, Swanstrom R.

Sci Transl Med. 2019 Oct 9;11(513). pii: eaaw5589. doi: 10.1126/scitranslmed.aaw5589.

PMID:
31597754
2.

HIV-Specific T Cell Responses Are Highly Stable on Antiretroviral Therapy.

Xu Y, Trumble IM, Warren JA, Clutton G, Abad-Fernandez M, Kirchnerr J, Adimora AA, Deeks SG, Margolis DM, Kuruc JD, Gay CL, Archin NM, Mollan KR, Hudgens M, Goonetilleke N.

Mol Ther Methods Clin Dev. 2019 Aug 14;15:9-17. doi: 10.1016/j.omtm.2019.07.008. eCollection 2019 Dec 13.

3.

In-vivo administration of histone deacetylase inhibitors does not impair natural killer cell function in HIV+ individuals.

Garrido C, Tolstrup M, Søgaard OS, Rasmussen TA, Allard B, Soriano-Sarabia N, Archin NM, Margolis DM.

AIDS. 2019 Mar 15;33(4):605-613. doi: 10.1097/QAD.0000000000002112.

PMID:
30830886
4.

Human Immunodeficiency Virus Type 1 RNA Detected in the Central Nervous System (CNS) After Years of Suppressive Antiretroviral Therapy Can Originate from a Replicating CNS Reservoir or Clonally Expanded Cells.

Joseph SB, Kincer LP, Bowman NM, Evans C, Vinikoor MJ, Lippincott CK, Gisslén M, Spudich S, Menezes P, Robertson K, Archin N, Kashuba A, Eron JJ, Price RW, Swanstrom R.

Clin Infect Dis. 2019 Sep 27;69(8):1345-1352. doi: 10.1093/cid/ciy1066.

PMID:
30561541
5.

HIV-Specific, Ex Vivo Expanded T Cell Therapy: Feasibility, Safety, and Efficacy in ART-Suppressed HIV-Infected Individuals.

Sung JA, Patel S, Clohosey ML, Roesch L, Tripic T, Kuruc JD, Archin N, Hanley PJ, Cruz CR, Goonetilleke N, Eron JJ, Rooney CM, Gay CL, Bollard CM, Margolis DM.

Mol Ther. 2018 Oct 3;26(10):2496-2506. doi: 10.1016/j.ymthe.2018.08.015. Epub 2018 Sep 21.

6.

HIV latency is reversed by ACSS2-driven histone crotonylation.

Jiang G, Nguyen D, Archin NM, Yukl SA, Méndez-Lagares G, Tang Y, Elsheikh MM, Thompson GR 3rd, Hartigan-O'Connor DJ, Margolis DM, Wong JK, Dandekar S.

J Clin Invest. 2018 Mar 1;128(3):1190-1198. doi: 10.1172/JCI98071. Epub 2018 Feb 19.

7.

HDAC inhibition induces HIV-1 protein and enables immune-based clearance following latency reversal.

Wu G, Swanson M, Talla A, Graham D, Strizki J, Gorman D, Barnard RJ, Blair W, Søgaard OS, Tolstrup M, Østergaard L, Rasmussen TA, Sekaly RP, Archin NM, Margolis DM, Hazuda DJ, Howell BJ.

JCI Insight. 2017 Aug 17;2(16). pii: 92901. doi: 10.1172/jci.insight.92901. eCollection 2017 Aug 17.

8.

Vorinostat Renders the Replication-Competent Latent Reservoir of Human Immunodeficiency Virus (HIV) Vulnerable to Clearance by CD8 T Cells.

Sung JA, Sholtis K, Kirchherr J, Kuruc JD, Gay CL, Nordstrom JL, Bollard CM, Archin NM, Margolis DM.

EBioMedicine. 2017 Sep;23:52-58. doi: 10.1016/j.ebiom.2017.07.019. Epub 2017 Jul 29.

9.

SLDAssay: A software package and web tool for analyzing limiting dilution assays.

Trumble IM, Allmon AG, Archin NM, Rigdon J, Francis O, Baldoni PL, Hudgens MG.

J Immunol Methods. 2017 Nov;450:10-16. doi: 10.1016/j.jim.2017.07.004. Epub 2017 Jul 18.

10.

Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency.

Archin NM, Kirchherr JL, Sung JA, Clutton G, Sholtis K, Xu Y, Allard B, Stuelke E, Kashuba AD, Kuruc JD, Eron J, Gay CL, Goonetilleke N, Margolis DM.

J Clin Invest. 2017 Aug 1;127(8):3126-3135. doi: 10.1172/JCI92684. Epub 2017 Jul 17.

11.

Immunogenicity of AGS-004 Dendritic Cell Therapy in Patients Treated During Acute HIV Infection.

Gay CL, DeBenedette MA, Tcherepanova IY, Gamble A, Lewis WE, Cope AB, Kuruc JD, McGee KS, Kearney MF, Coffin JM, Archin NM, Hicks CB, Eron JJ, Nicolette CA, Margolis DM.

AIDS Res Hum Retroviruses. 2018 Jan;34(1):111-122. doi: 10.1089/aid.2017.0071. Epub 2017 Jun 21.

12.

Proviral Latency, Persistent Human Immunodeficiency Virus Infection, and the Development of Latency Reversing Agents.

Margolis DM, Archin NM.

J Infect Dis. 2017 Mar 15;215(suppl_3):S111-S118. doi: 10.1093/infdis/jiw618. Review.

13.

Benzotriazoles Reactivate Latent HIV-1 through Inactivation of STAT5 SUMOylation.

Bosque A, Nilson KA, Macedo AB, Spivak AM, Archin NM, Van Wagoner RM, Martins LJ, Novis CL, Szaniawski MA, Ireland CM, Margolis DM, Price DH, Planelles V.

Cell Rep. 2017 Jan 31;18(5):1324-1334. doi: 10.1016/j.celrep.2017.01.022.

14.

Corrigendum: The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell function.

Clutton G, Xu Y, Baldoni PL, Mollan KR, Kirchherr J, Newhard W, Cox K, Kuruc JD, Kashuba A, Barnard R, Archin N, Gay CL, Hudgens MG, Margolis DM, Goonetilleke N.

Sci Rep. 2016 Oct 3;6:34430. doi: 10.1038/srep34430. No abstract available.

15.

Quantification of the Latent HIV-1 Reservoir Using Ultra Deep Sequencing and Primer ID in a Viral Outgrowth Assay.

Lee SK, Zhou S, Baldoni PL, Spielvogel E, Archin NM, Hudgens MG, Margolis DM, Swanstrom R.

J Acquir Immune Defic Syndr. 2017 Feb 1;74(2):221-228. doi: 10.1097/QAI.0000000000001187.

16.

The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell function.

Clutton G, Xu Y, Baldoni PL, Mollan KR, Kirchherr J, Newhard W, Cox K, Kuruc JD, Kashuba A, Barnard R, Archin N, Gay CL, Hudgens MG, Margolis DM, Goonetilleke N.

Sci Rep. 2016 Aug 2;6:30749. doi: 10.1038/srep30749. Erratum in: Sci Rep. 2016 Oct 03;6:34430.

17.

In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection.

Tsai P, Wu G, Baker CE, Thayer WO, Spagnuolo RA, Sanchez R, Barrett S, Howell B, Margolis D, Hazuda DJ, Archin NM, Garcia JV.

Retrovirology. 2016 May 21;13(1):36. doi: 10.1186/s12977-016-0268-7.

18.

Peripheral Vγ9Vδ2 T Cells Are a Novel Reservoir of Latent HIV Infection.

Soriano-Sarabia N, Archin NM, Bateson R, Dahl NP, Crooks AM, Kuruc JD, Garrido C, Margolis DM.

PLoS Pathog. 2015 Oct 16;11(10):e1005201. doi: 10.1371/journal.ppat.1005201. eCollection 2015 Oct.

19.

Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells.

Sung JA, Pickeral J, Liu L, Stanfield-Oakley SA, Lam CY, Garrido C, Pollara J, LaBranche C, Bonsignori M, Moody MA, Yang Y, Parks R, Archin N, Allard B, Kirchherr J, Kuruc JD, Gay CL, Cohen MS, Ochsenbauer C, Soderberg K, Liao HX, Montefiori D, Moore P, Johnson S, Koenig S, Haynes BF, Nordstrom JL, Margolis DM, Ferrari G.

J Clin Invest. 2015 Nov 2;125(11):4077-90. doi: 10.1172/JCI82314. Epub 2015 Sep 28.

20.

H3K27 Demethylation at the Proviral Promoter Sensitizes Latent HIV to the Effects of Vorinostat in Ex Vivo Cultures of Resting CD4+ T Cells.

Tripathy MK, McManamy ME, Burch BD, Archin NM, Margolis DM.

J Virol. 2015 Aug;89(16):8392-405. doi: 10.1128/JVI.00572-15. Epub 2015 Jun 3.

21.

Precise Quantitation of the Latent HIV-1 Reservoir: Implications for Eradication Strategies.

Crooks AM, Bateson R, Cope AB, Dahl NP, Griggs MK, Kuruc JD, Gay CL, Eron JJ, Margolis DM, Bosch RJ, Archin NM.

J Infect Dis. 2015 Nov 1;212(9):1361-5. doi: 10.1093/infdis/jiv218. Epub 2015 Apr 15.

22.

Staphylococcus aureus Infection in Humanized Mice: A New Model to Study Pathogenicity Associated With Human Immune Response.

Knop J, Hanses F, Leist T, Archin NM, Buchholz S, Gläsner J, Gessner A, Wege AK.

J Infect Dis. 2015 Aug 1;212(3):435-44. doi: 10.1093/infdis/jiv073. Epub 2015 Feb 5.

PMID:
25657257
23.

Expanded cytotoxic T-cell lymphocytes target the latent HIV reservoir.

Sung JA, Lam S, Garrido C, Archin N, Rooney CM, Bollard CM, Margolis DM.

J Infect Dis. 2015 Jul 15;212(2):258-63. doi: 10.1093/infdis/jiv022. Epub 2015 Jan 13.

24.

Eradicating HIV-1 infection: seeking to clear a persistent pathogen.

Archin NM, Sung JM, Garrido C, Soriano-Sarabia N, Margolis DM.

Nat Rev Microbiol. 2014 Nov;12(11):750-64. doi: 10.1038/nrmicro3352. Review.

25.

Broadly-specific cytotoxic T cells targeting multiple HIV antigens are expanded from HIV+ patients: implications for immunotherapy.

Lam S, Sung J, Cruz C, Castillo-Caro P, Ngo M, Garrido C, Kuruc J, Archin N, Rooney C, Margolis D, Bollard C.

Mol Ther. 2015 Feb;23(2):387-95. doi: 10.1038/mt.2014.207. Epub 2014 Nov 4.

26.

Quantitation of replication-competent HIV-1 in populations of resting CD4+ T cells.

Soriano-Sarabia N, Bateson RE, Dahl NP, Crooks AM, Kuruc JD, Margolis DM, Archin NM.

J Virol. 2014 Dec;88(24):14070-7. doi: 10.1128/JVI.01900-14. Epub 2014 Sep 24.

27.

Selective HDAC inhibition for the disruption of latent HIV-1 infection.

Barton KM, Archin NM, Keedy KS, Espeseth AS, Zhang YL, Gale J, Wagner FF, Holson EB, Margolis DM.

PLoS One. 2014 Aug 19;9(8):e102684. doi: 10.1371/journal.pone.0102684. eCollection 2014.

28.

HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat.

Archin NM, Bateson R, Tripathy MK, Crooks AM, Yang KH, Dahl NP, Kearney MF, Anderson EM, Coffin JM, Strain MC, Richman DD, Robertson KR, Kashuba AD, Bosch RJ, Hazuda DJ, Kuruc JD, Eron JJ, Margolis DM.

J Infect Dis. 2014 Sep 1;210(5):728-35. doi: 10.1093/infdis/jiu155. Epub 2014 Mar 11.

29.

Targeted cytotoxic therapy kills persisting HIV infected cells during ART.

Denton PW, Long JM, Wietgrefe SW, Sykes C, Spagnuolo RA, Snyder OD, Perkey K, Archin NM, Choudhary SK, Yang K, Hudgens MG, Pastan I, Haase AT, Kashuba AD, Berger EA, Margolis DM, Garcia JV.

PLoS Pathog. 2014 Jan;10(1):e1003872. doi: 10.1371/journal.ppat.1003872. Epub 2014 Jan 9.

30.

HLA-B*57 elite suppressor and chronic progressor HIV-1 isolates replicate vigorously and cause CD4+ T cell depletion in humanized BLT mice.

Salgado M, Swanson MD, Pohlmeyer CW, Buckheit RW 3rd, Wu J, Archin NM, Williams TM, Margolis DM, Siliciano RF, Garcia JV, Blankson JN.

J Virol. 2014 Mar;88(6):3340-52. doi: 10.1128/JVI.03380-13. Epub 2014 Jan 3.

31.

An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients.

Spina CA, Anderson J, Archin NM, Bosque A, Chan J, Famiglietti M, Greene WC, Kashuba A, Lewin SR, Margolis DM, Mau M, Ruelas D, Saleh S, Shirakawa K, Siliciano RF, Singhania A, Soto PC, Terry VH, Verdin E, Woelk C, Wooden S, Xing S, Planelles V.

PLoS Pathog. 2013;9(12):e1003834. doi: 10.1371/journal.ppat.1003834. Epub 2013 Dec 26.

32.

Emerging strategies to deplete the HIV reservoir.

Archin NM, Margolis DM.

Curr Opin Infect Dis. 2014 Feb;27(1):29-35. doi: 10.1097/QCO.0000000000000026. Review.

33.

HIV-1 infection, response to treatment and establishment of viral latency in a novel humanized T cell-only mouse (TOM) model.

Honeycutt JB, Wahl A, Archin N, Choudhary S, Margolis D, Garcia JV.

Retrovirology. 2013 Oct 24;10:121. doi: 10.1186/1742-4690-10-121.

34.

Reactivation of latent HIV-1 in central memory CD4⁺ T cells through TLR-1/2 stimulation.

Novis CL, Archin NM, Buzon MJ, Verdin E, Round JL, Lichterfeld M, Margolis DM, Planelles V, Bosque A.

Retrovirology. 2013 Oct 24;10:119. doi: 10.1186/1742-4690-10-119.

35.

Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.

Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, Parker DC, Anderson EM, Kearney MF, Strain MC, Richman DD, Hudgens MG, Bosch RJ, Coffin JM, Eron JJ, Hazuda DJ, Margolis DM.

Nature. 2012 Jul 25;487(7408):482-5. doi: 10.1038/nature11286. Erratum in: Nature. 2012 Sep 20;489(7416):460.

36.

BET bromodomain inhibition as a novel strategy for reactivation of HIV-1.

Banerjee C, Archin N, Michaels D, Belkina AC, Denis GV, Bradner J, Sebastiani P, Margolis DM, Montano M.

J Leukoc Biol. 2012 Dec;92(6):1147-54. doi: 10.1189/jlb.0312165. Epub 2012 Jul 16.

37.

Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection.

Archin NM, Vaidya NK, Kuruc JD, Liberty AL, Wiegand A, Kearney MF, Cohen MS, Coffin JM, Bosch RJ, Gay CL, Eron JJ, Margolis DM, Perelson AS.

Proc Natl Acad Sci U S A. 2012 Jun 12;109(24):9523-8. doi: 10.1073/pnas.1120248109. Epub 2012 May 29.

38.

Generation of HIV latency in humanized BLT mice.

Denton PW, Olesen R, Choudhary SK, Archin NM, Wahl A, Swanson MD, Chateau M, Nochi T, Krisko JF, Spagnuolo RA, Margolis DM, Garcia JV.

J Virol. 2012 Jan;86(1):630-4. doi: 10.1128/JVI.06120-11. Epub 2011 Oct 19.

39.

Latent HIV-1 infection of resting CD4⁺ T cells in the humanized Rag2⁻/⁻ γc⁻/⁻ mouse.

Choudhary SK, Archin NM, Cheema M, Dahl NP, Garcia JV, Margolis DM.

J Virol. 2012 Jan;86(1):114-20. doi: 10.1128/JVI.05590-11. Epub 2011 Oct 19.

40.

Epigenetic silencing of HIV-1 by the histone H3 lysine 27 methyltransferase enhancer of Zeste 2.

Friedman J, Cho WK, Chu CK, Keedy KS, Archin NM, Margolis DM, Karn J.

J Virol. 2011 Sep;85(17):9078-89. doi: 10.1128/JVI.00836-11. Epub 2011 Jun 29.

41.

Clonal sequences recovered from plasma from patients with residual HIV-1 viremia and on intensified antiretroviral therapy are identical to replicating viral RNAs recovered from circulating resting CD4+ T cells.

Anderson JA, Archin NM, Ince W, Parker D, Wiegand A, Coffin JM, Kuruc J, Eron J, Swanstrom R, Margolis DM.

J Virol. 2011 May;85(10):5220-3. doi: 10.1128/JVI.00284-11. Epub 2011 Mar 2.

42.

Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection.

Archin NM, Cheema M, Parker D, Wiegand A, Bosch RJ, Coffin JM, Eron J, Cohen M, Margolis DM.

PLoS One. 2010 Feb 23;5(2):e9390. doi: 10.1371/journal.pone.0009390.

43.

Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors.

Archin NM, Keedy KS, Espeseth A, Dang H, Hazuda DJ, Margolis DM.

AIDS. 2009 Sep 10;23(14):1799-806. doi: 10.1097/QAD.0b013e32832ec1dc.

44.

A limited group of class I histone deacetylases acts to repress human immunodeficiency virus type 1 expression.

Keedy KS, Archin NM, Gates AT, Espeseth A, Hazuda DJ, Margolis DM.

J Virol. 2009 May;83(10):4749-56. doi: 10.1128/JVI.02585-08. Epub 2009 Mar 11.

45.

Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid.

Archin NM, Espeseth A, Parker D, Cheema M, Hazuda D, Margolis DM.

AIDS Res Hum Retroviruses. 2009 Feb;25(2):207-12. doi: 10.1089/aid.2008.0191.

46.

Pharmaceutical approaches to eradication of persistent HIV infection.

Bowman MC, Archin NM, Margolis DM.

Expert Rev Mol Med. 2009 Feb 11;11:e6. doi: 10.1017/S1462399409000970. Review.

PMID:
19208267
47.

Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells.

Archin NM, Eron JJ, Palmer S, Hartmann-Duff A, Martinson JA, Wiegand A, Bandarenko N, Schmitz JL, Bosch RJ, Landay AL, Coffin JM, Margolis DM.

AIDS. 2008 Jun 19;22(10):1131-5. doi: 10.1097/QAD.0b013e3282fd6df4.

48.

Hexamethylbisacetamide and disruption of human immunodeficiency virus type 1 latency in CD4(+) T cells.

Choudhary SK, Archin NM, Margolis DM.

J Infect Dis. 2008 Apr 15;197(8):1162-70. doi: 10.1086/529525.

PMID:
18419522
49.

Eliminating persistent HIV infection: getting to the end of the rainbow.

Margolis DM, Archin NM.

J Infect Dis. 2007 Jun 15;195(12):1734-6. Epub 2007 May 2. No abstract available.

PMID:
17492587
50.

Attacking HIV provirus: therapeutic strategies to disrupt persistent infection.

Margolis DM, Archin NM.

Infect Disord Drug Targets. 2006 Dec;6(4):369-76. Review.

PMID:
17168802

Supplemental Content

Loading ...
Support Center